The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-18-Fluoromethylcholine or Ga-68-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy

Ur Metser; Sue Chua; Bao Ho; Shonit Punwani; Edward Johnston; Frederic Pouliot; Noam Tau; Asmaa Hawsawy; Reut Anconina; Glenn Bauman; Rodney J Hicks; Andrew Weickhardt; Ian D Davis; Greg Pond; AndrewM Scott; Nina Tunariu; Harbir Sidhu; Louise Emmett

Journal article

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-18-Fluoromethylcholine or Ga-68-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy

Ur Metser, Sue Chua, Bao Ho, Shonit Punwani, Edward Johnston, Frederic Pouliot, Noam Tau, Asmaa Hawsawy, Reut Anconina, Glenn Bauman, Rodney J Hicks, Andrew Weickhardt, Ian D Davis, Greg Pond, AndrewM Scott, Nina Tunariu, Harbir Sidhu, Louise Emmett

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2019

DOI: 10.2967/jnumed.118.225185

Abstract

Purpose: To assess whether the addition of data from multiparametric pelvic (mpMR) and whole body MR (wbMR) to the interpretation of 18F-fluoromethylcholine (FCH) or 68Ga-HBED-CC PSMA-11 (PSMA) PET/CT (=PET) improves the detection of local tumor recurrence, or nodal and distant metastases in patients following radical prostatectomy with biochemical failure. Methods: The current analysis was performed as part of a prospective, multicenter trial on FCH / PSMA PET, mpMR and wbMR. Eligible men had elevated PSA (>0.2 ng/ml) and high-risk features (Gleason score >7, PSA doubling time 1.0 ng/ml) with negative/ equivocal conventional imaging. PET was interpreted with mp&wbMR in consensus by 2 radiol..

View full abstract

University of Melbourne Researchers

Andrew Weickhardt Author Clinical Pathology

Andrew Scott Author Medicine - Austin Health

Rodney Hicks Author Medicine - St Vincent's Hospital

Ian Davis Author Medicine - Austin Health

Related Projects (1)

Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance

Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. Howe..

Grants

Funding Acknowledgements

We acknowledge the invaluable guidance and tireless support of Sam Gledhill of the Movember Foundation. Further thanks are given to the Society of Nuclear Medicine and Molecular Imaging team headed by Bonnie Clark for their role in the management of the imaging and data collection. We also acknowledge the support of local clinical trials teams in bringing together this project.